BriaCell Therapeutics Corp. BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCT

Rank in Stocks #24485
BriaCell Therapeutics Corp. is a biotechnology company focused on... BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Share Price
$3.68
Last synced: 2026-11-09
Market Cap
$32.16M
Change (1 day)
-6.64%
Change (1 year)
-54.60%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Trade BriaCell Therapeutics Corp. (BCT)

Category

Healthcare
EPS for BriaCell Therapeutics Corp. (BCT)
EPS as of July 2026 TTM: $-9.32
According to BriaCell Therapeutics Corp.'s latest financial reports, its current EPS (TTM) is $-9.32. At the end of 2025 the company had an EPS of $-62.95, a decrease compared to its 2024 EPS of $-43.68.
EPS history for BriaCell Therapeutics Corp. from 2007 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-9.32 -85.19%
2025 $-62.95 44.12%
2024 $-43.68 -77.60%
2023 $-195.00 -24.86%
2022 $-259.50 -44.49%
2021 $-467.51 -39.61%
2020 $-774.10 -31.78%
2019 $-1.13K -17.88%
2018 $-1.38K 28.09%
2017 $-1.08K 4.37%
2016 $-1.03K -39.92%
2015 $-1.72K -91.45%
2014 $-20.12K 1,315.57%
2013 $-1.42K -51.27%
2012 $-2.92K -36.69%
2011 $-4.61K -35.03%
2010 $-7.09K 74.44%
2009 $-4.06K 42.28%
2008 $-2.86K -31.84%
2007 $-4.19K 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -90.45%
US
$15.66 -268.03%
US
$-7.07 -24.14%
US
$-5.29 -43.24%
AU
$12.73 -236.61%
BE

Questions about BriaCell Therapeutics Corp.'s earnings per share (EPS)

What is BriaCell Therapeutics Corp.'s earnings per share (EPS)?

BriaCell Therapeutics Corp.'s earnings per share (EPS) over the last twelve months is $-9.32, as of Jul 2026.

What was BriaCell Therapeutics Corp.'s earnings per share (EPS) in 2025?

In 2025, BriaCell Therapeutics Corp.'s earnings per share (EPS) was $-62.95, compared with $-43.68 in 2024.

How has BriaCell Therapeutics Corp.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, BriaCell Therapeutics Corp.'s earnings per share (EPS) was highest in 2024 ($-43.68) and lowest in 2020 ($-774.10).

How does BriaCell Therapeutics Corp.'s earnings per share (EPS) compare with similar companies?

BriaCell Therapeutics Corp.'s earnings per share (EPS) ($-9.32) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.